Barclays
MDGL icon

Barclays’s Madrigal Pharmaceuticals MDGL Stock Holding History

Barclays’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,900
Closed -$4.21M – 5633
2025
Q2 		$4.21M Buy
+13,900
New +$4.14M ﹤0.01% 2269
2024
Q3 		– Sell
-300
Closed -$84K – 5403
2024
Q2 		$84K Sell
300
-8,700
-97% -$2.07M ﹤0.01% 3989
2024
Q1 		$2.4M Buy
+9,000
New +$2.12M ﹤0.01% 2418
2023
Q2 		– Sell
-17,600
Closed -$4.26M – 4867
2023
Q1 		$4.26M Buy
+17,600
New +$4.8M ﹤0.01% 1650
2019
Q2 		– Sell
-13,500
Closed -$1.69M – 7111
2019
Q1 		$1.69M Sell
13,500
-28,000
-67% -$3.48M ﹤0.01% 2751
2018
Q4 		$4.68M Buy
41,500
+20,500
+98% +$3.17M ﹤0.01% 1648
2018
Q3 		$4.5M Buy
21,000
+16,900
+412% +$4.24M ﹤0.01% 1919
2018
Q2 		$1.15M Buy
+4,100
New +$720K ﹤0.01% 3130
2015
Q4 		– Sell
-471
Closed -$17K – 6322
2015
Q3 		$17K Sell
471
-372
-44% -$26.8K ﹤0.01% 5543
2015
Q2 		$59K Buy
843
+283
+51% +$23.7K ﹤0.01% 5041
2015
Q1 		$20K Sell
560
-1,129
-67% -$96.8K ﹤0.01% 5831
2014
Q4 		$118K Sell
1,689
-754
-31% -$78K ﹤0.01% 5062
2014
Q3 		$257K Buy
2,443
+1,294
+113% +$180K ﹤0.01% 4517
2014
Q2 		$161K Sell
1,149
-617
-35% -$90.2K ﹤0.01% 5019
2014
Q1 		$247K Sell
1,766
-7,457
-81% -$1.47M ﹤0.01% 4590
2013
Q4 		$1.61M Sell
9,223
-6,206
-40% -$1.14M ﹤0.01% 2884
2013
Q3 		$3.24M Sell
15,429
-18,188
-54% -$3.87M ﹤0.01% 2088
2013
Q2 		$5.87M Buy
+33,617
New +$8.76M 0.01% 1493

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's MDGL Position: Q1 2026 in Review

Barclays reduced its Madrigal Pharmaceuticals (MDGL) stake by 91% in Q1 2026, selling an estimated $16.9M and leaving 3,376 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

Barclays first reported a position in MDGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.5M in Q4 2022. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Barclays held 3,376 shares of Madrigal Pharmaceuticals worth $1.77M as of Q1 2026.
  • Barclays sold 35,344 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2425 holding.
  • Barclays first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Madrigal Pharmaceuticals position peaked at $25.5M in Q4 2022.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.